4 research outputs found

    Implications of blood indices in systemic lupus erythematosus patients: Two feasible determinants of disease activity and lupus nephritis

    No full text
    Aim of the work: To investigate whether or not neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may by indicators of disease activity in systemic lupus erythematosus (SLE) with and without lupus nephritis (LN).Patients and methodsThis research was carried out on 40 adult SLE patients (20 with LN and 20 without) and 20 controls. The NLR and PLR were calculated. The SLE disease activity index (SLEDAI) was assessed.ResultsThe mean age of the patients was 36.2 ± 7.6 years, 38 females and 2 males (F:M 19:1), with a disease duration of4.3 ± 1.2 years. The mean SLEDAI was 15.1 ± 4.7 being significantly higher in those with LN (17.5 ± 3.5) compared to those without (12.6 ± 4.6) (p = 0.001). The mean NLR (6.1 ± 2.1) and PLR (236.6 ± 86.9) were significantly increased in patients compared to the control (2.7 ± 1.2 and 125.2 ± 38.8 respectively) (p < 0.001). The NLR and PLR were both significantly related to the serum creatinine (r = 0.35, p = 0.03 and r = 0.5, p = 0.001) and SLEDAI (r = 0.36, p = 0.03 and r = 0.34, p = 0.03 respectively). NLR can significantly predict activity of SLE at cut off 5.6 with a sensitivity 80%, specificity 65% (p = 0.007) and PLR at cut off 217 with sensitivity 75%, specificity 65% (p = 0.035). The NLR can significantly predict LN at cut off 3.6 (sensitivity 80%, specificity 40%; p = 0.007) and PLR at cut off 186 (sensitivity 70%, specificity 60%; p = 0.035).ConclusionThere is a remarkable link between PLR and NLR with SLEDAI. Thus, both may serve as promising affordable indicators of inflammation in SLE. The notable relation to LN may signal renal involvement in patients with SLE

    Serum calprotectin as a potential biomarker for subclinical enthesitis in psoriatic patients

    No full text
    Aim of the work: To assess serum calprotectin level in psoriatic patients and investigate its potential relation to clinical and ultrasonographic enthesitis. Patients and methods: The study included 45 psoriatic patients and 20 matched healthy controls. Enthesitis was assessed clinically, by musculoskeletal ultrasound (MSUS) and power Doppler, by Leeds Enthesitis Index (LEI), Maastricht Ankylosing Spondylitis Enthesitis (MASES), Spondyloarthritis Research Consortium of Canada (SPARCC) and Madrid Sonography Enthesitis Index (MASEI) scores. The Psoriasis Area, Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were evaluated. Serum calprotectin was measured using enzyme-linked immunosorbent assay. Results: The study included 45 psoriatic patients with a mean age of 49.9 ± 7.8 years and they were 23 males and 22 females with disease duration of 5.2 ± 3 years, (0.5–11 years). Patients were categorized into those with enthesitis (n = 25; 20 clinically and 5 subclinically diagnosed by MSUS) and those without (n = 20). Serum calprotectin was significantly higher among patients with enthesitis (clinical 593.7 ± 192.5 ng/ml and subclinical 692 ± 265.9 ng/ml) compared to those without (381.2 ± 198.5 ng/ml) and to the control (111.1 ± 15 ng/ml) (p = 0.001). The DLQI was significantly severer in patients with clinical enthesitis compared to those subclinically detected or without (p < 0.001). The acute phase reactants (erythrocyte sedimentation rate and C-reactive protein) were comparable between patients and control. Serum calprotectin significantly correlated with MASES, LEI, SPARCC and MASEI score in psoriatic patients (p < 0.001). At cutoff 141 ng/ml, calprotectin yielded specificity 69% and sensitivity 75% to detect enthesitis (p = 0.008). Conclusion: Calprotectin may be considered as a potential biomarker for detection of enthesitis in psoriatic patients

    Global economic burden of unmet surgical need for appendicitis

    No full text
    Background There is a substantial gap in provision of adequate surgical care in many low- and middle-income countries. This study aimed to identify the economic burden of unmet surgical need for the common condition of appendicitis. Methods Data on the incidence of appendicitis from 170 countries and two different approaches were used to estimate numbers of patients who do not receive surgery: as a fixed proportion of the total unmet surgical need per country (approach 1); and based on country income status (approach 2). Indirect costs with current levels of access and local quality, and those if quality were at the standards of high-income countries, were estimated. A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. Results Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. The economic burden of continuing current levels of access and local quality was US 92492millionusingapproach1and92 492 million using approach 1 and 73 141 million using approach 2. The economic burden of not providing surgical care to the standards of high-income countries was 95004millionusingapproach1and95 004 million using approach 1 and 75 666 million using approach 2. The largest share of these costs resulted from premature death (97.7 per cent) and lack of access (97.0 per cent) in contrast to lack of quality. Conclusion For a comparatively non-complex emergency condition such as appendicitis, increasing access to care should be prioritized. Although improving quality of care should not be neglected, increasing provision of care at current standards could reduce societal costs substantially

    Global economic burden of unmet surgical need for appendicitis

    No full text
    Background There is a substantial gap in provision of adequate surgical care in many low- and middle-income countries. This study aimed to identify the economic burden of unmet surgical need for the common condition of appendicitis. Methods Data on the incidence of appendicitis from 170 countries and two different approaches were used to estimate numbers of patients who do not receive surgery: as a fixed proportion of the total unmet surgical need per country (approach 1); and based on country income status (approach 2). Indirect costs with current levels of access and local quality, and those if quality were at the standards of high-income countries, were estimated. A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. Results Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. The economic burden of continuing current levels of access and local quality was US 92492millionusingapproach1and92 492 million using approach 1 and 73 141 million using approach 2. The economic burden of not providing surgical care to the standards of high-income countries was 95004millionusingapproach1and95 004 million using approach 1 and 75 666 million using approach 2. The largest share of these costs resulted from premature death (97.7 per cent) and lack of access (97.0 per cent) in contrast to lack of quality. Conclusion For a comparatively non-complex emergency condition such as appendicitis, increasing access to care should be prioritized. Although improving quality of care should not be neglected, increasing provision of care at current standards could reduce societal costs substantially
    corecore